{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Galsky MD"],"funding":["Parker Institute for Cancer Immunotherapy","Cancer Research Institute (CRI)","Prostate Cancer Foundation (PCF)","National Institutes of Health (NIH)","NCI NIH HHS","Prostate Cancer Foundation","Parker Institute for Cancer Immunotherapy (PICI)","National Institutes of Health","Cancer Research Institute"],"pagination":["1463-1475"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11995007"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(8)"],"pubmed_abstract":["<h4>Purpose</h4>Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer. Novel combinations may enhance immunotherapy efficacy.<h4>Patients and methods</h4>We conducted an open-label, noncomparative platform trial (NCT03835533) in metastatic castration-resistant prostate cancer to assess nivolumab-based combinations. The cohorts were as follows: (A) bempegaldesleukin 0.006 mg/kg and nivolumab 360 mg i.v. every 3 weeks; (B) stereotactic body radiotherapy 30 to 50 Gy, CDX-301 75 μg/kg s.c. for 5 days, poly-ICLC 1 mg intramuscularly weekly twice for 3 weeks, and nivolumab 480 mg every 4 weeks; and (C) CDX-301 75 μg/kg for 10 days, INO-5151 3 mg intramuscularly on lead-in day 8, day 1 of cycles 1 to 3, and then every 12 weeks, and nivoluma"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer."],"pmcid":["PMC11995007"],"funding_grant_id":["P30 CA008748","R35CA253175","R35 CA253175"],"pubmed_authors":["Autio KA","Graff JN","Friedlander TW","Densmore J","Wentzel K","Boffo S","Skolnik J","Yellin MJ","LaVallee TM","Da Silva DM","Fong L","Fairchild J","Galsky MD","Shotts KM","Spasic M","Lata J","Bhardwaj N","Chen RO","Subudhi SK","O'Donnell-Tormey J","Howes TR","Keler T","Cabanski CR","Dugan U"],"additional_accession":[]},"is_claimable":false,"name":"Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.","description":"<h4>Purpose</h4>Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer. Novel combinations may enhance immunotherapy efficacy.<h4>Patients and methods</h4>We conducted an open-label, noncomparative platform trial (NCT03835533) in metastatic castration-resistant prostate cancer to assess nivolumab-based combinations. The cohorts were as follows: (A) bempegaldesleukin 0.006 mg/kg and nivolumab 360 mg i.v. every 3 weeks; (B) stereotactic body radiotherapy 30 to 50 Gy, CDX-301 75 μg/kg s.c. for 5 days, poly-ICLC 1 mg intramuscularly weekly twice for 3 weeks, and nivolumab 480 mg every 4 weeks; and (C) CDX-301 75 μg/kg for 10 days, INO-5151 3 mg intramuscularly on lead-in day 8, day 1 of cycles 1 to 3, and then every 12 weeks, and nivoluma","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T20:42:25.069Z","creation":"2025-07-03T03:04:20.374Z"},"accession":"S-EPMC11995007","cross_references":{"pubmed":["39964352"],"doi":["10.1158/1078-0432.CCR-24-3693"]}}